CAR-T clinical trials for Neuroendocrine Cancer (plus bonus section on CAR-NK)
Update 24th August 2026 "Chimeric Halts CAR T-cell Trial Enrolment, Shifts Approach" Chimeric Therapeutics has now stopped enrolment and dosing in the Phase 1 trial after side effects were observed at the highest dose level. The company will not continue developing this version of the CAR T-cell therapy but believes CDH17 remains a valid target and plans to pursue a new in vivo approach. So, what happens next? Chimeric is now advancing a different approach: an in vivo delivery method for a CDH17-directed CAR T-cell therapy. Rather than modifying a patient’s T cells outside the body, as in the current trial,…